Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
금요일, 9월 04

Alnylam Pharmaceuticals Inc

ALNYNASDAQ
Trade with Public
Trade with Public
$263.02
-1.48-0.56%
마지막 업데이트: Sep 4, 1:31 PM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Alnylam Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Alnylam Pharmaceuticals (ALNY).

Price Target Range — 7 Quarters

Analyst Consensus — 22 Analysts

1S.Buy
19Buy
2Hold
Consensus RatingBuy# Analysts22Avg. Consensus PT$421Upside to Avg. PT+60.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 2, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$455
Aug 19, 2026BMO CapitalDavid LebowitzInitiateOutperform$318
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.
Benzinga Newsdesk

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Avi Kapoor

PRO
BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform rating and announces Price Target of $318.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $316 to $256.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $315

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $410 to $315.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $455

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $485 to $455.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved